Safety Profile of S1P Receptor Modulators for Multiple Sclerosis
Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).
EP: 1.S1P Receptor Modulators and the Treatment Landscape of Relapsing-Remitting Multiple Sclerosis
EP: 2.Tissue Selectivity of S1P Receptor Modulator
Now Viewing
EP: 3.Safety Profile of S1P Receptor Modulators for Multiple Sclerosis
EP: 4.Monitoring Patients With Relapsing-Remitting Multiple Sclerosis on S1P Receptor Modulator
EP: 5.Switching Patients With Multiple Sclerosis to S1P Receptor Modulator
EP: 6.The Safety Data of Ozanimod in Multiple Sclerosis
EP: 7.The Safety of Other S1P Receptor Modulators in Multiple Sclerosis
EP: 8.Clinical Pearls for Treating Relapsing-Remitting Multiple Sclerosis With S1P Receptor Modulators
EP: 9.S1P Receptor Modulators in Multiple Sclerosis
EP: 10.Selecting S1P Receptor Modulators in Multiple Sclerosis
EP: 11.Long-term Data With Ozanimod in Relapsing-Remitting Multiple Sclerosis
EP: 12.Long-Term Data With Other S1P Receptor Modulators in Multiple Sclerosis
EP: 13.Long-term Immunological Impact of Drug-Modifying Therapies in Multiple Sclerosis
EP: 14.Expert Advice on Multiple Sclerosis Treatment Cessation and Disease Rebound
EP: 15.Emerging Disease-Modifying Therapy Data in Multiple Sclerosis
EP: 16.Final Thoughts on S1P Receptor Modulators in Multiple Sclerosis
Recent Videos
Related Content
